Nicholas Scarpa, MD
Rheumatology · Jersey City, NJNPI 1770523433
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $256,757 of the $280,881 with a category attached, or 91.4%. 20 manufacturers reported payments, led by AbbVie at 51.3% of the total. Reporting peaked in 2023 at $88,483 and has fallen 76.2% since, to $21,071 in 2025. Among rheumatology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,020 payments — averaging $275.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$144K
- Lilly USA, LLC$93K
- Pfizer$18K
- Amgen$15K
- Bristol Myers Squibb$5K
- Novartis$2K
- plus $4K from 14 others
What the payments were for
- Consulting fees$2,8081%
- Speaking & faculty fees$256,75791%
- Travel & lodging$2,4211%
- Food & beverage$18,3757%
- Education$5210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 308 | $144,162 |
| Lilly USA, LLC | 135 | $92,525 |
| Pfizer | 146 | $18,103 |
| Amgen(2 entities) | 125 | $15,170 |
| Bristol Myers Squibb | 13 | $5,369 |
| Novartis | 81 | $1,654 |
| Johnson & Johnson(2 entities) | 78 | $1,345 |
| E.r. Squibb & Sons, L.L.C. | 57 | $973 |
| GSK | 31 | $428 |
| Genentech USA, Inc. | 10 | $190 |
| UCB, Inc. | 12 | $189 |
| Sanofi | 11 | $172 |
| Mallinckrodt Hospital Products Inc. | 1 | $135 |
| Sun Pharmaceutical Industries Inc. | 1 | $132 |
| Janssen Scientific Affairs, LLC | 1 | $116 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Ferring Pharmaceuticals Inc. | 6 | $81 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Medexus Pharma, Inc. | 1 | $13 |
| Radius Health, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$280,881 in reported general payments places this provider in the 95th percentile of 234 rheumatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 106 | $765,327 |
| Enbrel SureclickEtanercept | 88 | $693,008 |
| Humira(Cf) PenAdalimumab | 68 | $476,900 |
| SimponiGolimumab | 39 | $414,265 |
| Xeljanz XrTofacitinib Citrate | 53 | $292,373 |
| Humira(Cf)Adalimumab | 21 | $171,996 |
| Taltz AutoinjectorIxekizumab | 21 | $155,496 |
| EnbrelEtanercept | 16 | $134,720 |
| OrenciaAbatacept | 22 | $124,491 |
| ProliaDenosumab | 20 | $35,508 |
| Hydroxychloroquine Sulfate | 356 | $14,349 |
| Diclofenac Sodium | 225 | $12,965 |
| SavellaMilnacipran Hcl | 20 | $9,514 |
| Leflunomide | 147 | $7,964 |
| MethotrexateMethotrexate Sodium | 267 | $6,176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Savella | $144,162 | $946,837147 claims |
| Johnson & JohnsonSimponi | $1,345 | $414,26539 claims |
| AmgenEnbrel, Prolia | $15,170 | $170,22836 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $973 | $124,49122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 234 rheumatology providers in New Jersey.
Other rheumatology in Jersey City
- Frederick BrandtJersey City$10K
- Lori CoxNew Brunswick$1.4M
- Richard HaddadRed Bank$1.1M
- Kiren SahniWest Long Branch$569K
- Jeffrey GreenbergSummit$399K
- Steven GolombekDover$318K
- Adrienne HollanderVoorhees$214K
- Edward AllegraRed Bank$212K
- Nickolas TyrisSewell$201K
- Anan HaijaGalloway$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.